Shots:

• Immunogenicity data are available for the 25µg & 100µg dose level (aged 18-55yrs.) after two doses (day 43) and at the 25µg level after one dose (day 29). All the participants are seroconverted by day15 following a single dose- @43day 2wks. following the second dose- at the 25µg- levels of binding Abs were at the levels seen in convalescent sera while at 100µg-  levels of binding Abs exceeded the levels seen in convalescent sera
• Neutralizing Ab data are available only for the first four participants in each of the 25µg & 100µg dose level cohorts. mRNA-1273 vaccination elicited neutralizing Abs in all eight of participants- as measured by PRNT assays. mRNA-1273 was safe and well-tolerated
• Following interim P-I data- P-II study will be amended to study two dose levels- 50 & 100 µg- with the aim of selecting a dose for pivotal studies. The anticipated dose for P-III study to be b/w 25µg & 100 µg- expected to be initiated in July

Click here ­to­ read full press release/ article | Ref: Moderna | Image: Moderna

Related News: Moderna’s mRNA-1273 Receives the US FDA’s Fast Track Designation to Treat COVID-19